Interestingly, the fraction of DNMT3A R882 mutations of all DNMT3A variants in MDS fell between that of CHIP and AML (27%, p<.001 when compared with either CHIP or AML). This evidence concerns the gene DNMT3A and acute myeloid leukemia.